Literature DB >> 27671337

Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance.

Yang Zhan1,2, Guanyi Zhang3, Xiaojie Wang1, Yanfeng Qi2, Shanshan Bai1,2, Dongying Li3, Tianfang Ma1,2, Oliver Sartor4,5, Erik K Flemington3, Haitao Zhang3, Peng Lee6, Yan Dong7,2.   

Abstract

Androgen receptor splice variants (AR-V) are implicated in resistance of prostate cancer to androgen-directed therapies. When expressed alone in cells, some AR-Vs (e.g., AR-V7) localize primarily to the nucleus, whereas others (e.g., AR-V1, AR-V4, and AR-V6) localize mainly to the cytoplasm. Significantly, the latter are often coexpressed with the nucleus-predominant AR-Vs and the full-length AR (AR-FL). An important question to be addressed is whether the cytoplasmic-localized AR-Vs play a role in castration-resistant prostate cancer (CRPC) through interaction with the nucleus-predominant AR-Vs and AR-FL. Here, it is demonstrated that AR-V1, -V4, and -V6 can dimerize with both AR-V7 and AR-FL. Consequently, AR-V7 and androgen-bound AR-FL induced nuclear localization of AR-V1, -V4, and -V6, and these variants, in turn, mitigated the ability of the antiandrogen enzalutamide to inhibit androgen-induced AR-FL nuclear localization. Interestingly, the impact of nuclear localization of AR-V4 and -V6 on AR transactivation differs from that of AR-V1. Nuclear localization leads to an increased ability of AR-V4 and -V6 to transactivate both canonical AR targets and AR-V-specific targets and to confer castration-resistant cell growth. However, although AR-V1, which lacks inherent transcriptional activity, appears to activate AR-FL in an androgen-independent manner, it significantly antagonizes AR-V7 transactivation. Together, these data demonstrate that the complex interactions among different AR-Vs and AR-FL play a significant role in castration-resistant disease. IMPLICATIONS: This study suggests important consequences for clinical castration resistance due to simultaneous expression of AR-FL and AR-Vs in patient tumors and suggests that dissecting these interactions should help develop effective strategies to disrupt AR-V signaling. Mol Cancer Res; 15(1); 59-68. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27671337      PMCID: PMC5215946          DOI: 10.1158/1541-7786.MCR-16-0236

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  39 in total

1.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

2.  Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.

Authors:  Siu Chiu Chan; Yingming Li; Scott M Dehm
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

3.  Monitoring protein-protein interactions in living cells by bioluminescence resonance energy transfer (BRET).

Authors:  Fadi F Hamdan; Yann Percherancier; Billy Breton; Michel Bouvier
Journal:  Curr Protoc Neurosci       Date:  2006-02

4.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

5.  Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.

Authors:  Xi Yang; Zhiyong Guo; Feng Sun; Wei Li; Alan Alfano; Hermela Shimelis; Mingyuan Chen; Angela M H Brodie; Hegang Chen; Zhen Xiao; Timothy D Veenstra; Yun Qiu
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

6.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.

Authors:  Duo Xu; Yang Zhan; Yanfeng Qi; Bo Cao; Shanshan Bai; Wei Xu; Sanjiv S Gambhir; Peng Lee; Oliver Sartor; Erik K Flemington; Haitao Zhang; Chang-Deng Hu; Yan Dong
Journal:  Cancer Res       Date:  2015-06-09       Impact factor: 12.701

7.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

Review 8.  Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Authors:  Karen E Knudsen; Howard I Scher
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

9.  Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.

Authors:  Guanyi Zhang; Xichun Liu; Jianzhuo Li; Elisa Ledet; Xavier Alvarez; Yanfeng Qi; Xueqi Fu; Oliver Sartor; Yan Dong; Haitao Zhang
Journal:  Oncotarget       Date:  2015-09-15

10.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.

Authors:  David T Miyamoto; Yu Zheng; Ben S Wittner; Richard J Lee; Huili Zhu; Katherine T Broderick; Rushil Desai; Douglas B Fox; Brian W Brannigan; Julie Trautwein; Kshitij S Arora; Niyati Desai; Douglas M Dahl; Lecia V Sequist; Matthew R Smith; Ravi Kapur; Chin-Lee Wu; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728

View more
  31 in total

Review 1.  Allosteric alterations in the androgen receptor and activity in prostate cancer.

Authors:  Takuma Uo; Stephen R Plymate; Cynthia C Sprenger
Journal:  Endocr Relat Cancer       Date:  2017-09       Impact factor: 5.678

2.  RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.

Authors:  William C Reinhold; Sudhir Varma; Margot Sunshine; Fathi Elloumi; Kwabena Ofori-Atta; Sunmin Lee; Jane B Trepel; Paul S Meltzer; James H Doroshow; Yves Pommier
Journal:  Cancer Res       Date:  2019-05-21       Impact factor: 12.701

3.  Nuclear loss and cytoplasmic expression of androgen receptor in penile carcinomas: role as a driver event and as a prognosis factor.

Authors:  Hellen Kuasne; Mateus C Barros-Filho; Fábio A Marchi; Sandra A Drigo; Cristovam Scapulatempo-Neto; Eliney F Faria; Silvia R Rogatto
Journal:  Virchows Arch       Date:  2018-08-11       Impact factor: 4.064

4.  Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.

Authors:  Manish Kohli; Yeung Ho; David W Hillman; Jamie L Van Etten; Christine Henzler; Rendong Yang; Jamie M Sperger; Yingming Li; Elizabeth Tseng; Ting Hon; Tyson Clark; Winston Tan; Rachel E Carlson; Liguo Wang; Hugues Sicotte; Ho Thai; Rafael Jimenez; Haojie Huang; Peter T Vedell; Bruce W Eckloff; Jorge F Quevedo; Henry C Pitot; Brian A Costello; Jin Jen; Eric D Wieben; Kevin A T Silverstein; Joshua M Lang; Liewei Wang; Scott M Dehm
Journal:  Clin Cancer Res       Date:  2017-05-04       Impact factor: 12.531

5.  Androgenic modulation of AR-Vs.

Authors:  Ana Caroline Hillebrand; Lolita Schneider Pizzolato; Gisele Branchini; Ilma Simoni Brum
Journal:  Endocrine       Date:  2018-07-19       Impact factor: 3.633

6.  Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression.

Authors:  Anees M Dauki; James S Blachly; Esko A Kautto; Sameera Ezzat; Mohamed H Abdel-Rahman; Christopher C Coss
Journal:  Cancer Res       Date:  2019-11-04       Impact factor: 12.701

Review 7.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

8.  Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.

Authors:  Suriyan Ponnusamy; Christopher C Coss; Thirumagal Thiyagarajan; Kate Watts; Dong-Jin Hwang; Yali He; Luke A Selth; Iain J McEwan; Charles B Duke; Jayaprakash Pagadala; Geetika Singh; Robert W Wake; Christopher Ledbetter; Wayne D Tilley; Tudor Moldoveanu; James T Dalton; Duane D Miller; Ramesh Narayanan
Journal:  Cancer Res       Date:  2017-10-04       Impact factor: 12.701

Review 9.  Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Authors:  Jun Luo; Gerhardt Attard; Steven P Balk; Charlotte Bevan; Kerry Burnstein; Laura Cato; Artem Cherkasov; Johann S De Bono; Yan Dong; Allen C Gao; Martin Gleave; Hannelore Heemers; Mayuko Kanayama; Ralf Kittler; Joshua M Lang; Richard J Lee; Christopher J Logothetis; Robert Matusik; Stephen Plymate; Charles L Sawyers; Luke A Selth; Howard Soule; Wayne Tilley; Nancy L Weigel; Amina Zoubeidi; Scott M Dehm; Ganesh V Raj
Journal:  Eur Urol       Date:  2017-12-16       Impact factor: 20.096

10.  Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.

Authors:  Jiaqian Liang; Liyang Wang; Larysa Poluben; Mannan Nouri; Seiji Arai; Lisha Xie; Olga S Voznesensky; Laura Cato; Xin Yuan; Joshua W Russo; Henry W Long; Myles Brown; Shaoyong Chen; Steven P Balk
Journal:  Cancer Lett       Date:  2021-07-10       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.